|
Forecast Period
|
2025-2029
|
|
Market Size (2023)
|
USD 522.01 million
|
|
Market Size (2029)
|
USD 789.29 million
|
|
CAGR (2024-2029)
|
7.10%
|
|
Fastest Growing Segment
|
Single-channel
|
|
Largest Market
|
North-East
|
Market Overview
United States Deep Brain Stimulation In Parkinson’s
Disease Market was valued at USD 522.01 million in 2023 and is anticipated to
project impressive growth in the forecast period with a CAGR of 7.10% through
2029. The rising incidence of Parkinson's Disease (PD) is a significant driving
force behind the growth of the deep brain stimulation devices market. PD is the
second most prevalent neurodegenerative disorder after Alzheimer's Disease
(AD). Its development is influenced by a combination of genetic factors, such
as mutations in the alpha-synuclein gene, and environmental factors, including
repeated head injuries, with aging being the primary risk factor. The COVID-19
pandemic has had adverse effects on market expansion, impacting both demand and
production directly. It disrupted supply chains and imposed financial
challenges on businesses. During the pandemic, there was consistent
postponement or cancellation of neurological surgeries to prevent the spread of
COVID-19. Neurosurgical procedures saw a 55% decline in the most severely
affected countries, including the United States, Russia, India, Brazil, France,
the United Kingdom, Italy, and Spain. There is increasing evidence suggesting
that the COVID-19 virus can lead to symptoms such as brain fog and other
neurological issues.
Key Market Drivers
Increasing Prevalence of Parkinson's Disease
Parkinson's Disease (PD) is a progressively
debilitating neurological condition that affects millions of individuals
worldwide. In the United States, as in many other countries, the prevalence of
Parkinson's Disease is on the rise. This alarming increase in the number of
people affected by PD is not only a public health concern but also a
significant driver behind the growth of the United States Deep Brain
Stimulation (DBS) in Parkinson's Disease market. Parkinson's Disease is characterized
by motor symptoms such as tremors, bradykinesia, rigidity, and postural
instability. It is a progressive condition that affects the central nervous
system, leading to a deterioration in quality of life. The exact cause of
Parkinson's Disease remains unknown, but both genetic and environmental factors
are believed to play a role. One of the most concerning aspects of PD is its
increasing prevalence, which has a profound impact on healthcare systems and
treatment options.
One of the primary factors contributing to the rising
prevalence of Parkinson's Disease is the aging population. As the Baby Boomer
generation continues to age, there is a natural increase in the number of
individuals at risk for PD. The disease primarily affects people over the age
of 60, and with longer life expectancies, a greater portion of the population
is entering the age range where PD is more common. Advancements in medical
technology and diagnostic criteria have led to earlier and more accurate
diagnoses of Parkinson's Disease. This means that individuals who may not have
been identified in the past are now receiving proper diagnoses and care. This
early detection increases the demand for effective treatments, including DBS. In
addition to aging, environmental factors such as exposure to certain pesticides
and industrial chemicals have been associated with an increased risk of
developing Parkinson's Disease. As environmental factors continue to play a
role, the prevalence of the disease is likely to rise, further driving the
demand for effective therapies like DBS. DBS is a surgical procedure that
involves implanting electrodes into specific areas of the brain and connecting
them to a pulse generator, which delivers controlled electrical impulses. This
technique has shown remarkable effectiveness in managing the motor symptoms of
Parkinson's Disease, providing patients with improved quality of life and
functional independence. With a larger pool of individuals diagnosed with
Parkinson's Disease, there is a growing number of potential candidates for DBS
therapy.
The greater the number of patients, the higher the demand for this
advanced treatment option. As awareness of Parkinson's Disease and its
treatment options spreads, more healthcare providers and medical institutions
are equipped to offer DBS procedures. This improved access to care ensures that
eligible patients have the opportunity to explore DBS as a treatment choice. The
rising prevalence of Parkinson's Disease has prompted increased research and
investment in the development of advanced DBS technologies and techniques. This
innovation not only enhances the efficacy of DBS but also expands its potential
applications to address a wider range of neurological conditions.
Effectiveness of Deep Brain Stimulation
Deep Brain Stimulation (DBS) has emerged as a
transformative therapeutic approach in the management of Parkinson's Disease
(PD). This innovative treatment has demonstrated remarkable effectiveness in
alleviating the motor symptoms of PD, significantly improving patients' quality
of life. In the United States, the effectiveness of DBS is a driving force
behind the growth of the DBS market for Parkinson's Disease. Deep Brain
Stimulation (DBS) has emerged as a transformative therapeutic approach in the
management of Parkinson's Disease (PD). This innovative treatment has
demonstrated remarkable effectiveness in alleviating the motor symptoms of PD, significantly
improving patients' quality of life. In the United States, the effectiveness of
DBS is a driving force behind the growth of the DBS market for Parkinson's
Disease. The primary reason behind the growing popularity of DBS in the United
States is its proven efficacy in managing the motor symptoms of Parkinson's
Disease. DBS involves the implantation of electrodes into specific regions of
the brain, which are connected to a pulse generator. This device delivers
controlled electrical impulses, effectively modulating the brain circuits
responsible for PD symptoms. Patients who undergo DBS often experience
significant improvements in their motor symptoms, including reduced tremors,
enhanced mobility, and better overall motor function. DBS not only provides
immediate relief but also offers prolonged and lasting benefits. Many patients
find that their motor symptoms remain well-managed for several years following
the procedure. This prolonged effectiveness is a crucial factor in boosting
patient confidence in DBS as a long-term solution for PD management. Another
significant advantage of DBS is its potential to reduce the reliance on
medication. As DBS provides substantial symptom relief, patients may be able to
reduce the dosage of their Parkinson's medications. This can lead to fewer
medication-related side effects, enhancing the overall quality of life for
individuals with PD. Perhaps the most compelling aspect of DBS therapy is its
profound impact on the quality of life for Parkinson's patients. Beyond motor
symptom management, DBS can improve non-motor symptoms such as mood, cognition,
and sleep. This holistic approach to PD management contributes to an improved
overall well-being for patients and their caregivers. As the effectiveness of
DBS becomes more widely recognized, the demand for this therapy continues to
surge. Patients who have exhausted traditional medication options or are
seeking a more comprehensive approach to symptom management are increasingly
turning to DBS as a viable solution. Advancements in the field of neurology are
expanding the eligibility criteria for DBS beyond the traditional stages of PD.
As researchers uncover new insights into the brain circuits involved in PD, DBS
is being considered for use in earlier stages of the disease and for a broader
range of symptoms. This expansion in eligibility criteria further contributes
to the growth of the DBS market. The remarkable effectiveness of DBS therapy
has spurred significant investments in research and development within the
medical device industry. Companies are continually innovating and improving DBS
technology, making it even more precise, customizable, and accessible. These
advancements fuel the growth of the DBS market in the United States.
Expanding Clinical Indications
Deep Brain Stimulation (DBS) has long been
recognized as a highly effective treatment for Parkinson's Disease (PD).
However, its potential extends far beyond this one application. In recent
years, there has been a noteworthy expansion in the clinical indications for
DBS, particularly in the United States. This expansion is proving to be a
significant driver for the growth of the DBS market, as the therapy's
versatility attracts the attention of both healthcare providers and patients
alike. DBS was initially developed as a treatment primarily for PD, with a
focus on alleviating the motor symptoms of the disease. However, its mechanism
of action – the precise modulation of neural circuits through targeted
electrical impulses – has broadened its potential applications in various
neurological and neuropsychiatric conditions. One of the first significant
expansions beyond PD was the application of DBS in treating essential tremor
(ET). Essential tremor is a neurological disorder characterized by
uncontrollable shaking, often affecting the hands and head. DBS has
demonstrated remarkable efficacy in reducing or even eliminating these tremors,
offering a life-changing improvement in the quality of life for ET patients.
As
a result, DBS has become an accepted treatment option for ET, boosting its
adoption and the growth of the DBS market. Dystonia is another neurological
condition characterized by involuntary muscle contractions, leading to abnormal
postures and repetitive movements. DBS has proven to be a game-changer in
dystonia management, providing relief to patients who have struggled with
debilitating symptoms for years. This expanded application has not only
improved patient outcomes but has also widened the reach of DBS in the United
States. Expanding the clinical indications for DBS has brought hope to
individuals with severe, treatment-resistant obsessive-compulsive disorder
(OCD). In recent years, studies have shown that DBS can effectively alleviate
OCD symptoms in select cases. While this application is still in its early
stages and requires further research, it has sparked interest in the potential
of DBS to address other neuropsychiatric conditions. DBS has also demonstrated
promise in the field of epilepsy management, particularly for patients who do
not respond to traditional treatments like medication or are not suitable
candidates for surgical resection. By modulating specific brain circuits, DBS
may help reduce the frequency and severity of seizures in some epilepsy
patients. As research continues in this area, the potential for DBS to become a
viable epilepsy treatment option grows.
The expansion of clinical indications
for DBS has led to increased adoption of this therapy among both healthcare
providers and patients. Physicians who previously focused solely on PD now
consider DBS for a broader range of conditions, leading to more referrals and
procedures. As DBS becomes applicable to a wider range of neurological and
neuropsychiatric conditions, the patient pool for this therapy expands significantly.
This increased demand fosters market growth, as more individuals seek the
benefits of DBS. The growing clinical indications for DBS have spurred
investment in research and development. Companies are exploring new
technologies, electrode configurations, and stimulation parameters to optimize
DBS for various conditions. This innovation not only enhances the efficacy of
DBS but also opens the door to potential future applications.
Healthcare Infrastructure and Accessibility
The United States has long been at the forefront of
medical innovation and technological advancement. In recent years, this
leadership has extended to the realm of Deep Brain Stimulation (DBS), a
groundbreaking therapy for Parkinson's Disease (PD). One crucial factor driving
the growth of the DBS market for PD in the United States is the robust
healthcare infrastructure and the accessibility it offers to patients in need. The
United States boasts a well-established healthcare infrastructure that includes
specialized centers and medical institutions dedicated to neurology and
neurosurgery. These centers provide patients with access to highly trained
neurologists and neurosurgeons who are experienced in the diagnosis and
treatment of neurological conditions, including PD. The presence of these
experts ensures that patients receive the best possible care and guidance when
considering DBS as a treatment option. In addition to expert healthcare
providers, the United States offers access to state-of-the-art medical
facilities and equipment. The availability of advanced imaging techniques, such
as functional MRI and diffusion tensor imaging, allows for precise
pre-operative planning and accurate targeting of brain regions during DBS
procedures. These facilities enhance the safety and efficacy of DBS surgeries,
making the therapy even more appealing to patients and healthcare providers.
Healthcare
infrastructure in the United States is closely tied to insurance coverage. Many
insurance plans provide coverage for DBS procedures, making the therapy
financially accessible to a broader range of patients. This insurance support
reduces the financial burden on patients and encourages them to consider DBS as
a viable treatment option. The United States' vast geographical reach means
that patients from various regions can access specialized healthcare services,
including DBS treatment. Major metropolitan areas are typically equipped with
comprehensive healthcare facilities, but even patients in more remote areas
have the opportunity to access these services, thanks to well-connected
healthcare networks. The accessibility of healthcare infrastructure extends to
clinical trials and research initiatives. The United States hosts numerous
clinical trials related to DBS and PD, allowing patients to participate in
groundbreaking research and gain access to cutting-edge treatments. This
accessibility to research opportunities not only benefits patients but also
contributes to the growth of the DBS market by advancing the field. Healthcare
infrastructure in the United States includes patient education and support
programs that help individuals, and their families make informed decisions
about treatment options like DBS. Patients can access resources, attend support
groups, and engage with healthcare professionals who can guide them through the
entire treatment journey. This support system is crucial in boosting patient
confidence and increasing the adoption of DBS therapy.
Download Free Sample Report
Key Market Challenges
Limited Awareness and Education
One of the foremost challenges facing the DBS
market in the United States is limited awareness among patients and even some
healthcare providers. Many individuals with PD, especially those in the early
stages of the disease, may not be aware of DBS as a treatment option.
Healthcare providers also vary in their familiarity with DBS therapy, which can
impact referrals and access to treatment. Comprehensive patient education and
awareness campaigns are crucial to address this challenge and ensure that
eligible patients are informed about DBS.
High Cost of Treatment
The cost associated with DBS procedures can be a
significant barrier to access. While some insurance plans cover the cost of
DBS, not all patients may have adequate coverage. Additionally, the
out-of-pocket expenses, including co-pays and deductibles, can be substantial.
The high upfront cost of the device itself, coupled with surgical and follow-up
expenses, can deter some patients from pursuing DBS as a treatment option.
Efforts to reduce the financial burden on patients, such as improved insurance
coverage and cost-effective device options, are needed.
Access Disparities
Access to specialized healthcare and DBS treatment
can vary significantly across different regions of the United States. While
major metropolitan areas typically have comprehensive healthcare facilities,
rural and underserved areas may lack access to neurologists, neurosurgeons, and
DBS centers. This access disparity can result in delayed diagnosis and
treatment for individuals living in these regions. Initiatives to improve
healthcare infrastructure and expand access to specialized care are essential
to address this challenge.
Ongoing Device Maintenance
DBS devices require ongoing maintenance and
programming adjustments to ensure optimal therapeutic outcomes. Regular
check-ups with specialized healthcare providers are necessary for patients with
DBS implants. However, these follow-up appointments can be logistically
challenging, especially for patients who live far from DBS centers.
Telemedicine and remote programming options are emerging as potential solutions
to improve access to device maintenance.
Key Market Trends
Expanding Clinical Indications
One of the most promising trends on the horizon is
the expanding range of clinical indications for DBS. While DBS initially gained
recognition as a treatment for PD, ongoing research is revealing its potential
for addressing other neurological and neuropsychiatric disorders. In the United
States, we can expect to see an increasing number of clinical trials and
studies exploring the use of DBS in conditions such as essential tremor,
dystonia, obsessive-compulsive disorder (OCD), epilepsy, and even depression.
These expanded clinical indications will open up new avenues for DBS, increasing
its relevance and adoption.
Miniaturization of Devices
Advancements in medical technology are driving the
miniaturization of DBS devices. Smaller, more discreet devices are in
development, allowing for less invasive implantation procedures. These miniaturized
devices offer improved patient comfort, reduced scarring, and potentially fewer
post-operative complications. As these devices become available, we can expect
an increase in patient acceptance and adoption of DBS therapy.
Closed-Loop DBS Systems
Closed loop or adaptive DBS systems represent a
significant advancement in DBS technology. These systems use real-time data
feedback to adjust stimulation parameters automatically based on a patient's
specific needs. By providing dynamic, patient-centered therapy, closed-loop DBS
systems have the potential to enhance symptom control and reduce side effects.
Expectations are high for the adoption of closed-loop DBS systems as they
become more refined and widely available.
Patient-Centered Outcomes and Quality of Life
As the focus on patient-centered care continues to
grow, the DBS market will increasingly emphasize patient-reported outcomes and
quality of life measures. Beyond just symptom management, healthcare providers
will aim to improve the overall well-being and satisfaction of patients
undergoing DBS therapy. This trend aligns with the broader shift towards
holistic healthcare approaches that prioritize the patient's experience and
outcomes.
Segmental Insights
Product Insights
Based on the category of Product, the dual-channel
system dominated the market. High-frequency Deep Brain Stimulation (DBS) has
emerged as a widely adopted approach for managing severe movement disorders
when medical treatments no longer yield improvements. This procedure is known
for its safety, bilaterality, and reversibility, involving the insertion of
leads into target areas on both sides of the brain. The increasing acceptance
of double-channel DBS for addressing various neurological conditions like Parkinson's
disease, dystonia, Alzheimer's disease, and epilepsy is a significant driver of
growth in this segment.
Besides, advancements in technology and the
introduction of new products are also contributing to the segment's expansion.
For example, in January 2020, Abbott's Infinity DBS system gained FDA approval
for treating Parkinson's disease, allowing precise targeting of the brain's
internal Globus Pallidus (GPi) associated with Parkinson's symptoms. Notable
offerings in this segment include Boston Scientific's Vercise, Vercise PC, and
Vercise Gevia DBS systems, Medtronic's Activa PC and Activa RC, and Abbott's
Infinity.
The single-channel segment is expected to
experience the most rapid growth in the foreseeable future. Deep Brain
Stimulator (DBS) devices, also known as brain pacemakers, have been used
clinically for 25 years to treat Parkinson's disease. Single-channel DBS
systems are employed in patients with only one lead implanted. Healthcare
professionals prefer single-channel systems because they offer neurologists
more programming flexibility and deliver better motor outcomes.
Factors such as the increasing elderly population,
which is more susceptible to Parkinson's disease, and greater awareness of
neurological movement disorders among patients are expected to drive growth in
this segment. For instance, the World Ageing 2019 report estimated that there
were approximately 703 million individuals aged 65 or older globally in 2019.
Additionally, the Brain & Spine Foundation (BSF) and Neurological Alliance
launched "Brain Awareness Week" in March 2018, a global campaign
aimed at raising awareness about advancements in the diagnosis, treatment, and
prevention of neurological conditions. One of the noteworthy products in this
segment is Medtronic's Activa SC, a single-channel DBS approved for Parkinson's
disease treatment.
Download Free Sample Report
Regional Insights
The North-East region of the United States is
poised to assert its dominance in the Deep Brain Stimulation (DBS) market for
Parkinson's Disease treatment due to a combination of key factors. Firstly,
this region is home to some of the nation's most prestigious medical
institutions and research centers, where groundbreaking innovations in
neurology and DBS technology are consistently developed. These institutions
attract top-tier talent and foster a culture of medical excellence, ensuring
that cutting-edge treatments like DBS are readily available and widely adopted.
Additionally, the North-East region boasts a dense population of elderly
individuals, who are more prone to Parkinson's disease, creating a substantial
patient base for DBS procedures. Lastly, the region's strong healthcare
infrastructure and a well-informed populace contribute to a high level of
awareness and demand for advanced treatments like DBS. All these factors
combined make the North-East region a formidable force in shaping the future of
the DBS market for Parkinson's Disease within the United States.
Recent Developments
- In February 2022, Aleva Neurotherapeutics, a
company specializing in implants for deep brain stimulation (DBS) to address
critical neurological conditions such as essential tremor and Parkinson's
disease, announced the acquisition of FDA approval for an Investigational
Device Exemption (IDE) research program. This protocol greenlights the
collection of data concerning the effectiveness and safety of their device in
preparation for a future Premarket Approval (PMA) application. The FDA granted
this approval following an extensive exchange of information between the agency
and Aleva, wherein all clinical data and safety assessments underwent
comprehensive scrutiny. Consequently, this development is poised to stimulate
market growth in the foreseeable future.
Key Market Players
- Boston Scientific Corporation
- Abbott
Laboratories Inc
- Medtronic plc
- Functional
Neuromodulation Inc
- Nuvectra
Corp
- Aleva
Neurotherapeutics SA
|
By Product
|
By Region
|
- Single-channel
- Dual-channel
|
- North-East
- Mid-West
- West
- South
|
Report Scope:
In this report, the United States Deep Brain
Stimulation In Parkinson’s Disease Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- United States Deep Brain Stimulation In
Parkinson’s Disease Market, By
Product:
o Single-channel
o Dual-channel
- United States Deep Brain Stimulation In
Parkinson’s Disease Market, By Region:
o North-East
o Mid-West
o West
o South
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the United
States Deep Brain Stimulation In Parkinson’s Disease Market.
Available Customizations:
United States Deep Brain Stimulation In Parkinson’s
Disease market report with the given market data, Tech Sci Research
offers customizations according to a company's specific needs. The following
customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
United States Deep
Brain Stimulation In Parkinson’s Disease Market is an upcoming report to be
released soon. If you wish an early delivery of this report or want to confirm
the date of release, please contact us at [email protected]